David J. Wilson Acquires 31,300 Shares of Columbus McKinnon Co. (NASDAQ:CMCO) Stock
by Scott Moore · The Cerbat GemColumbus McKinnon Co. (NASDAQ:CMCO – Get Free Report) CEO David J. Wilson purchased 31,300 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average price of $32.02 per share, for a total transaction of $1,002,226.00. Following the completion of the transaction, the chief executive officer now directly owns 31,300 shares of the company’s stock, valued at $1,002,226. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Columbus McKinnon Stock Down 1.7 %
Shares of CMCO stock traded down $0.54 during trading hours on Monday, hitting $31.42. 301,704 shares of the company’s stock traded hands, compared to its average volume of 177,236. The company has a quick ratio of 1.20, a current ratio of 2.04 and a debt-to-equity ratio of 0.50. The stock has a market cap of $901.44 million, a price-to-earnings ratio of 59.30 and a beta of 1.19. The stock’s fifty day simple moving average is $33.23 and its two-hundred day simple moving average is $36.21. Columbus McKinnon Co. has a 12-month low of $29.26 and a 12-month high of $45.84.
Columbus McKinnon Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, November 18th. Shareholders of record on Friday, November 8th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Friday, November 8th. Columbus McKinnon’s dividend payout ratio (DPR) is 52.83%.
Hedge Funds Weigh In On Columbus McKinnon
Institutional investors and hedge funds have recently modified their holdings of the stock. Foundry Partners LLC increased its position in shares of Columbus McKinnon by 23.9% during the first quarter. Foundry Partners LLC now owns 121,625 shares of the industrial products company’s stock valued at $5,428,000 after acquiring an additional 23,460 shares in the last quarter. Boston Partners bought a new stake in shares of Columbus McKinnon in the 1st quarter worth $847,000. First Eagle Investment Management LLC raised its stake in shares of Columbus McKinnon by 11.7% in the first quarter. First Eagle Investment Management LLC now owns 184,281 shares of the industrial products company’s stock worth $8,224,000 after purchasing an additional 19,350 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in shares of Columbus McKinnon during the first quarter valued at $3,791,000. Finally, Vanguard Group Inc. boosted its position in shares of Columbus McKinnon by 1.0% during the first quarter. Vanguard Group Inc. now owns 1,557,371 shares of the industrial products company’s stock valued at $69,505,000 after buying an additional 16,174 shares during the last quarter. 95.96% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, StockNews.com cut shares of Columbus McKinnon from a “buy” rating to a “hold” rating in a report on Friday, August 2nd.
Check Out Our Latest Analysis on CMCO
About Columbus McKinnon
Columbus McKinnon Corporation designs, manufactures, and markets motion solutions for moving, lifting, positioning, and securing materials worldwide. It offers manual, battery, electric, and air hoists; steel, rack, and pinion jacks; winches, hydraulic jacks and tools, trolleys and its clamps, and lifting tables; skates and heavy load moving systems; material handling equipment; mobile, workplace, and jib cranes; crane components and kits; and below-the-hook lifting devices, lifting slings, and lashing systems.
See Also
- Five stocks we like better than Columbus McKinnon
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Intel: Is Now the Time to Be Brave?
- Best Aerospace Stocks Investing
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How Investors Can Find the Best Cheap Dividend Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?